乳腺浸润性导管癌中SATB1、NF-KB p65及HER-2蛋白的表达及其与临床病理的相关性

doi:10.3969/j.issn.1671-7171.2021.06.012

摘要
图/表
参考文献(30)
相关文章 (15)

全文: PDF (1747 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要【目的】探讨乳腺浸润性导管癌中特异性核基质结合区结合蛋白1(special AT-rich binding protein 1,SATB1)、核转录因子-κB p65(nuclear transcription factor-kappa B,NF-κB p65)及人上皮生长因子受体2(human epidermal growth factor receptor 2,HER-2)的表达及其与临床病理参数的相关性。【方法】利用免疫组化检测90例乳腺浸润性导管癌及癌旁组织中SATB1、NF-κB及HER-2蛋白的表达;对HER-2蛋白中度阳性者利用荧光原位杂交(fluorescence in situ hybridization,FISH)检测HER-2基因的扩增。分析SATB1、NF-κB p65及HER-2的表达与临床病理参数的相关性。【结果】SATB1、NF-KB p65及HER-2蛋白在乳腺癌组织中的阳性表达率分别为71%(64/90)、53.3%(48/90)和30%(27/90),明显高于癌旁组织。SATB1和NF-κB p65蛋白表达与肿瘤大小、组织学分级、TNM分期、腋窝淋巴结转移及雌激素受体(estrogen receptor,ER)表达状态有关,而与患者年龄无关。Her-2基因过表达仅与腋窝淋巴结转移有关(P<0.05),而与肿瘤大小、组织学分级、TNM分期、ER表达状态及年龄无关。在乳腺浸润性导管癌中SATB1和NF-κB p65蛋白的表达呈显著正相关,HER-2的表达与SATB1和NF-KB p65蛋白之间均未见明显相关性。【结论】SATB1和NF-KB p65蛋白表达与浸润性导管癌的临床病理参数密切相关,它们在乳腺癌的发生发展中具有协同作用,有可能作为乳腺浸润性导管癌的预后指标。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	王文忠
	李瑜辉
	谭兵

关键词 ：乳腺肿瘤/病理学, 肿瘤蛋白质类, 转录因子RelA, 受体,erbB-2, 预后

Abstract：【Objective】To investigate the expression patterns of Special AT-rich binding protein 1(SATB1), nuclear factor-kappa B p65(NF-κB p65) and HER-2 in invasive ductal breast carcinoma, and their correlation with the clinical and pathological Parameters.【Methods】The protein expression of SATB1, NF-κB p65 and HER-2 were examined by immunohistochemistry, and fluorescence in situ hybridization (FISH) was employed to detect HER2 amplification. 【Results】The expression rates of SATB1, NF-κB p65 and HER-2 in 90 cases of invasive ductal breast carcinoma were 71%(64/90), 53.3%(48/90) and 30%(27/90) respectively, and higher in comparison to normal breast tissues. The expression of SATB1 and NF-κB p65 were correlated with tumor size, histological classification, TNM stage, lymph node metastasis and ER status, and not associated with age. The over-expression of HER-2 was only correlated with lymph node metastasis, but not associated with tumor size, histological classification, TNM stage, ER status and age. The positive correlation was found between the expression of SATB1 and NF-κB, but HER2 expression was not significantly correlated with that of other proteins. 【Conclusion】The expression of SATB1 and NF-κB were closely correlated with clinical and pathological parameters of invasive ductal breast carcinoma, and may have synergistic effect in during the occurrence and development of breast carcinoma. The expression of SATB1 and NF-κB may be used as prognostic biomarkers of invasive ductal breast carcinoma.

Key words： Breast Neoplasms/PA Neoplasm Proteins Transcription Factor RelA Receptor, ErbB-2 Prognosis

收稿日期: 2021-05-06

中图分类号:

R737.9

引用本文:

王文忠, 李瑜辉, 谭兵. 乳腺浸润性导管癌中SATB1、NF-KB p65及HER-2蛋白的表达及其与临床病理的相关性[J]. 医学临床研究, 2021, 38(6): 846-850.
WANG Wen-zhong, LI Yu-hui, TAN Bing. SATB1, NF-κB and HER-2 Expression Patterns in Invasive Ductal Breast Carcinoma and Their Correlation with Clinical and Pathological Parameters. JOURNAL OF CLINICAL RESEARCH, 2021, 38(6): 846-850.

链接本文:

http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2021.06.012 或 http://journal07.magtech.org.cn/yxlcyj/CN/Y2021/V38/I6/846

[1] JEMAL A, BRAY F, CENTER M M,et al.Global cancer statistics[J].CA Cancer J Clin,2011, 61(2):69-90.
[2] ALVAREZ J D, YASUI D H, NIIDA H, et al.The MAR-binding protein SATB1 orchestrates temporal and spatial expression of multiple genes during T-cell development[J].Genes Dev,2000, 14(5):521-535.
[3] HAN HJ, RUSSO J, KOHWI Y, et al.SATB1 reprogrammes gene expression to promote breast tumour growth and metastasis[J].Nature,2008, 452(7184):187-193.
[4] CHEN F, CASTRANOVA V, SHI X, et al.New insights into the role of nuclear factor-kappaB, a ubiquitous transcription factor in the initiation of diseases[J].Clin Chem,1999, 45(1):7-17.
[5] CHEN F, CASTRANOVA V, SHI X.New insights into the role of nuclear factor-kappaB in cell growth regulation[J].Am J Pathol,2001, 159(2):387-397.
[6] MERKHOFER E C, COGSWELL P, BALDWIN A S.Her2 activates NF-kappaB and induces invasion through the canonical pathway involving IKKalpha[J].Oncogene,2010, 29(8):1238-1248.
[7] QIU J, WANG X, GUO X,et al.Toll-like receptor 9 agonist inhibits ERalpha-mediated transactivation by activating NF-kappaB in breast cancer cell lines[J].Oncol Rep,2009, 22(4):935-941.
[8] ROSKOSKI R JR.The ErbB/HER family of protein-tyrosine kinases and cancer[J].Pharmacol Res,2014, 79:34-74.
[9] IQBAL N, IQBAL N.Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers:Overexpression and Therapeutic Implications[J].Mol Biol Int,2014,852748.
[10] REMMELE W, STEGNER H E.Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue[J].Pathologe,1987,8(3):138-140.
[11] XU L, DENG H X, XIA J H, et al.Assignment of SATB1 to human chromosome band 3p23 by in situ hybridization[J].Cytogenet Cell Genet,1997, 77(3-4):205-206.
[12] GUO L, ZHENG J, YU T, et al.Elevated expression of SATB1 is involved in pancreatic tumorigenesis and is associated with poor patient survival[J].Mol Med Rep,2017,16(6):8842-8848.
[13] GLATZEL-PLUCI SKA N, PIOTROWSKA A, DZI GIEL P, et al.The role of SATB1 in tumour progression and metastasis[J].Int J Mol Sci,2019, 20(17):E4156.
[14] FRÖMBERG A, ENGELAND K, AIGNER A.The Special AT-rich sequence binding protein 1 (SATB1) and its role in solid tumors[J].Cancer Lett,2018, 417:96-111.
[15] IORNS E, HNATYSZYN H J, SEO P, et al.The role of SATB1 in breast cancer pathogenesis[J].J Natl Cancer Inst,2010, 102(16):1284-1296.
[16] 赵莉娟,白中红,许软成.乳腺癌患者核基质结合区结合蛋白1和核因子相关蛋白κB的表达水平及其相关性分析[J].癌症进展,2018,16(3):324-327.
[17] ORDINARIO E, HAN H J, FURUTA S, et al.ATM suppresses SATB1-induced malignant progression in breast epithelial cells[J].PLoS One,2012, 7(12):e51786.
[18] LEVIDOU G, KORKOLOPOULOU P, NIKITEAS N, et al.Expression of nuclear factor kappaB in human gastric carcinoma:relationship with I kappaB a and prognostic significance[J].Virchows Arch,2007,450(5):519-527.
[19] SMOLI SKA M, GRZANKA D, ANTOSIK P, et al.HER2, NF-κB, and SATB1 expression patterns in gastric cancer and their correlation with clinical and pathological parameters[J].Dis Markers,2019, 2019:6315936.
[20] BISWAS D K, SHI Q, BAILY S,et al.NF-kappa B activation in human breast cancer specimens and its role in cell proliferation and apoptosis[J].Proc Natl Acad Sci USA,2004, 101(27):10137-10142.
[21] ZANG Y Q, FENG Y Y, LUO Y H, et al.Quinalizarin induces ROS mediated apoptosis via the MAPK, STAT3 and NFκB signaling pathways in human breast cancer cells[J].Mol Med Rep,2019, 20(5):4576-4586.
[22] CHEN C, YANG J M, HU T T, et al.Prognostic role of human epidermal growth factor receptor in gastric cancer:a systematic review and meta-analysis[J].Arch Med Res,2013, 44(5):380-389.
[23] BEGNAMI M D, FUKUDA E, FREGNANI J H,et al.Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas:HER2 and HER3 are predictors of poor outcome[J].J Clin Oncol,2011, 29(22):3030-3036.
[24] JANJIGIAN Y Y, WERNER D, PAULIGK C, et al.Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status:a European and USA International collaborative analysis[J].Ann Oncol,2012, 23(10):2656-2662.
[25] GÓ MEZ-MARTIN C, GARRALDA E, ECHARRI M J, et al.HER2/neu testing for anti-HER2-based therapies in patients with unresectable and/or metastatic gastric cancer[J].J Clin Pathol,2012, 65(8):751-757.
[26] ARIGA R, ZARIF A, KORASICK J, et al.Correlation of her-2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma[J].Breast J,2005, 11(4):278-280.
[27] KUSTIC D, LOVASIC F, BELAC-LOVASIC I, et al.Impact of HER2 receptor status on axillary nodal burden in patients with non-luminal A invasive ductal breast carcinoma[J].Rev Med Chil,2019, 147(5):557-567.
[28] LI Q Q, CHEN Z Q, XU J D, et al.Overexpression and involvement of special AT-rich sequence binding protein 1 in multidrug resistance in human breast carcinoma cells[J].Cancer Sci,2010, 101(1):80-86.
[29] LIU X, ZHENG Y, QIAO C, et al. Expression of SATB1 and HER2 in breast cancer and the correlations with clinicopathologic characteristics[J].Diagn Pathol,2015, 10:50.
[30] BAILEY S T.NF-κB activation-induced anti-apoptosis renders HER2-positive cells drug resistant and accelerates tumor growth[J].Mol Cancer Res,2014, (3):408-420.